On Monday, Intec Pharma (NASDAQ: NTEC) said it is to merge with privately-held, preclinical-stage biotechnology company Decoy Biosystems, Inc.
Intec Pharma’s share price surged on the announcement, opening at $7.34 before falling to where it is now sitting at $5.92, up 31.85%.
Intec said the combined company will advance its immunotherapy platform to battle various tumour types and chronic viral infections.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Decoy, which is developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumour and anti-viral immune responses, held a pre-IND meeting with the FDA and plans to file an IND in the second half of 2021 and to initiate a Phase 1 clinical trial in 2022 targeting solid tumours and lymphomas.
Once the merger is completed, Decoy’s stockholders will own approximately 75% of the combined company, with Intec shareholders expected to hold about 25%.
The combined company is expected to be led by Jeffrey Meckler as Chief Executive Officer and Michael Newman as Chief Scientific Officer, with Dr Roger Pomerantz serving as Chairman.
“This transformative transaction provides Intec with a robust clinical pipeline based on a novel immunotherapy platform and gives Intec entrée into the exciting area of immuno-oncology,” said Jeffrey Meckler, Vice Chairman and CEO of Intec Pharma.
